Malmö 27 February 2024 **PRESS RELEASE**

Aptahem's scientific manuscript in collaboration with the research group at UHN in Toronto has been approved for publication in the journal Cells

The ground-breaking results from the studies performed with the drug candidate Apta-1, in collaboration with the research group at University Health Network (UHN) in Toronto, in various serious disease models have now lead to a first approval for publication.

The collaboration with the group in Toronto, lead by Professor Mingyao Liu, and from Aptahem Dr Luiza Jedlina, has been ongoing for some time and included several study steps in a SARS (Severe Acute Respiratory Syndrome) Corona lung model, which Aptahem previously has reported. The SARS Corona virus which has been used in the studies is an approximately 10 times more lethal virus than the one causing Covid-19.

As a lung virus infection can lead to a sepsis condition, this manuscript, which now has been accepted for publication the scientific journal Cells, marks an important milestone for Aptahem. The title of the article is "*Therapeutic effects of a novel aptamer on coronaviral infection induced lung injury and systemic inflammatory responses*". Cells has an impact factor of 6-7, which makes it top 10% of all journals. Publication date will be communicated at a later stage.

CEO Mikael Lindstam comments:
"I am very pleased to receive this news as we have been working long and hard for this. As Apta-1 is a complex, multi-mechanistic drug candidate which requires far more studies than might be believed normal it has taken some time to evaluate. With this confirmation after all years' work with both ground research and preclinical studies both in-house and in various collaborations, we view this as a breakthrough and a support for potentially future publications and for the discussions we can have with stakeholders."

For further information:
Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com

About Aptahem
Aptahem AB (APTA) is a clinical stage biotechnology company that develops RNA-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company's lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com.